InflaRx N.V.

We are a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, an inherent part of the innate immune system. We discover, develop and commercialize first-in-class, highly potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With our therapeutic product candidates in clinical development, vilobelimab and izicopan (formerly known as INF904), we target C5a and its receptor C5aR to selectively to inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. We discovered and developed both products candidates through our own internal efforts. Our legal and commercial name is InflaRx N.V. and we were incorporated under the laws of the Netherlands on June 6, 2017, and our headquarters, as registered with the local court of Jena, is located in Jena, Germany. InflaRx was founded in 2007 as InflaRx GmbH by Professor Niels Riedemann and Professor Renfeng Guo in Jena, Germany. Our agent for service of process in the United States is InflaRx Pharmaceuticals, Inc. located at 600 South Wagner Road, Ann Arbor, Michigan 48103. Our principal executive offices and laboratories are located in Winzerlaer Str. 2, 07745 Jena, Germany, telephone: +49 3641 508 180. We have additional offices in Planegg-Martinsried (Munich), Germany and in Ann Arbor, Michigan, United States, where we also have laboratories. As of December 31, 2025, we employed a total of 65 employees, 22 of whom have M.D. or Ph.D.